Skip to main content

Table 3 Characteristics of patients with moderate to severe airflow limitation

From: Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease

 

Patients with moderate to severe AFL (n = 61)

LAMA/LABA

LAMA

p value*

No-BD

p value**

n = 32

n = 22

n = 7

Age

72. 2 ± 6.7

70.8 ± 6.6

0.236

69.9 ± 5.6

0.406

Sex

  

0.804

 

0.929

 Male

27 (84.4)

18 (81.8)

 

6 (85.7)

 

 Female

5 (15.6)

4 (18.2)

 

1 (14.3)

 

Smoking status

  

0.412

 

0.262

 Current smoker

11 (34.4)

10 (45.5)

 

4 (57.1)

 

 Ex-smoker

21 (65.6)

12 (54.5)

 

3 (42.9)

 

Severity of AFL

  

0.344

 

0.399

 Moderate

29 (90.6)

18 (81.8)

 

7 (100)

 

 Severe

3 (9.4)

4 (18.2)

 

0

 

Comorbidities

     

 Cardiovascular disease

16 (50.0)

13 (59.1)

0.510

6 (85.7)

0.084

 Diabetes mellitus

6 (18.8)

6 (27.3)

0.459

3 (42.9)

0.170

Surgical procedure

  

0.098

 

0.887

 Lobectomy

26 (81.3)

22 (100)

 

6 (85.7)

 

 Segmentectomy

1 (3.1)

0

 

0

 

 Partial resection

5 (15.6)

0

 

1 (14.3)

 

Pathologic staging

  

0.016

 

0.148

 I

26 (81.3)

11 (50.0)

 

4 (57.1)

 

 II

2 (6.3)

8 (36.4)

 

0

 

 III

4 (12,5)

3 (13.6)

 

3 (42.9)

 

Adjuvant chemotherapy

4 (12.5)

5 (22.7)

0.322

2 (28.6)

0.286

Recurrence (present)

4 (12.5)

10 (45.5)

0.006

4 (57.1)

0.008

 Treatment for recurrence

     

 Anticancer drug

2

7

 

3

 

 Molecular targeted drug

0

1

 

1

 

 None

2

2

 

0

 
  1. Data are presented as n (%) or as mean ± SD
  2. COPD chronic obstructive pulmonary disease; LAMA long-acting muscarinic antagonists; LABA long-acting β2-agonists; BD bronchodilator; AFL airflow limitation